UNSPSC 51392005: Fenoldopam mesilate or mesylate

This classification denotes a dopamine agonist with the molecular formula C16H16ClNO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HA3R0MY016, chemically known as 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt), but more generally known as fenoldopam mesylate, which bears US NIH Compound Identifier 3341. European Medicines Agency schedules fenoldopam mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07577MIG.

UNSPSC 51392005 Fenoldopam mesilate or mesylate is a Commodity code that in recent state and local procurement activity does not reflect purchases aligned with its pharmaceutical-ingredient scope. The two most recent opportunities tagged to this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—involve broader pharmacy benefit procurement, overdose-response products, and pharmaceutical supply-chain management rather than fenoldopam mesilate specifically. State and local buyers under this code span county health departments and state health agencies. The mismatch between the code's nominal scope and the actual work posted suggests that the code may be misapplied in state and local systems or that recent activity does not reflect fenoldopam mesilate demand.

Activity appears concentrated in Florida and Texas based on the recent records. Seminole County posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with a one-year renewal option; the procurement requires quarterly deliveries and includes shipping in the bid price. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capability data on direct-to-manufacturer prescription programs for self-insured employer and state health plans, with no formal evaluation timeline or award amount specified. The code shows limited recent relevant activity for fenoldopam mesilate procurement in state and local markets.